Overcoming Analytical Bottlenecks In Oligonucleotide Drug Development With Automation

By Arielle Mann, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

Oligonucleotide therapeutics are reshaping modern drug development, but the industry still faces major barriers in the downstream analysis required to bring these complex molecules to market. As synthesis scales up and molecular designs grow more intricate, analytical teams are overwhelmed by high‑volume datasets, manual MS workflows, and impurity profiles that demand expert interpretation. These bottlenecks limit throughput, slow decision‑making, and strain resources across biopharma organizations.

A recent collaboration demonstrates how automated LC‑UV‑MS processing can dramatically streamline this landscape, cutting analysis times, expanding impurity characterization, and freeing scientists to focus on higher‑value work. The results point to a scalable path forward for organizations navigating similar challenges.

Explore how automated workflows can reduce analytical burden, enhance data quality, and accelerate oligonucleotide development from early characterization through optimization.